by David Gortler, Activist Post:
Back in the early 2000s, the FDA launched the Safety First Steering Committee (SFSC). It was started to address the safety concerns of marketed drugs of noteworthy concern to Americans. Today, the acronym is still found ubiquitously throughout FDA documents, but those links no longer function.
It appears to have been replaced by the Drug Risk Management Board (DRMB). The DRMB has no public-facing web page, but it appears that the DRMB is just a rebranded SFSC.
TRUTH LIVES on at https://sgtreport.tv/
Per the FDA:
“The DRMB is a cross-CDER governance board responsible for three key objectives: (1) facilitating and coordinating decisions around major product safety issues, (2) providing clear and consistent guidance enabling an appropriate response to major safety issues, and (3) systematically communicating decisions and resulting actions across the Center and to other stakeholders as appropriate. In addition, the DRMB facilitates and coordinates all new and existing marketed product-safety initiatives.”
The Drug Safety Monitoring Board was chaired by Dr. Patrizia Cavazzoni, the head of the FDA’s Center for Drug Evaluation and Research (CDER). Cavazzoni unexpectedly resigned just hours prior to Donald Trump’s inauguration on Jan 20th, 2025.
Although neither the DRMB staff nor meeting minutes are made public, the FDA Drug Safety Priority annual reports are. One of the more conspicuous things missing from those reports over the past decade or so is any mention of the widespread off-label promotion of hormone modulators (also referred to as GnRH modulators or puberty blockers) and/or cross-sex hormones in kids, in the name of “gender transition.”
It’s not really a surprise that Cavazzoni – a psychiatrist and former Big Pharma employee for nearly two decades prior to joining the FDA – would turn a blind eye to drug safety based on politics. During her leadership, Cavazzoni enacted questionable political regulatory decisions and advanced other Biden/Harris White House policies including multiple ineffective and dangerous Alzheimer’s disease products, as well as demanding cruel animal testing in place of newer, animal-free methodology.
As the chairwoman of the DRMB, Cavazzoni should objectively determine what is a priority. Cavazzoni determined that tens of thousands of puberty-blocking transgender drug adverse events – including deaths, hospitalizations, and permanent disabilities – simply aren’t a “Drug Risk Monitoring Board” priority.
